| Latest Genelabs Technologies News Headlines | | Date | Time | Source | | | 01/07/2009 | 8:50AM | PRNUS | GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.
LONDON, Jan. 7 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) announced today the successful completion of the tender offer by its wholly-owned subsidiary Gemstone Acquisition Corporation for shares of common stock of Genelabs Technologies, Inc. (NASDAQ:GNLB). The tender offer expired at 12:00 midnight... More...>> |
| 12/15/2008 | 9:00AM | PRNUS | GlaxoSmithKline Further Extends Tender Offer to Acquire Genelabs Technologies, Inc.
LONDON, Dec. 15 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that it has extended its previously announced tender offer to purchase all of the outstanding shares of common stock of Genelabs Technologies, Inc. (NASDAQ:GNLB), for $1.30 in cash per share without interest and less any required... More...>> |
| 12/15/2008 | 9:00AM | PRNUS | GlaxoSmithKline Further Extends Tender Offer to Acquire Genelabs Technologies, Inc.
LONDON, Dec. 15 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that it has extended its previously announced tender offer to purchase all of the outstanding shares of common stock of Genelabs Technologies, Inc. (NASDAQ:GNLB), for $1.30 in cash per share without interest and less any required... More...>> |
| 12/08/2008 | 9:11AM | PRNUS | GlaxoSmithKline Extends Tender Offer for Genelabs Technologies, Inc.
LONDON, and PHILADELPHIA, Dec. 8 /PRNewswire-FirstCall/ -- GlaxoSmithKline (LSE/NYSE: GSK) announced today that it has extended its previously announced tender offer to purchase all of the outstanding shares of common stock of Genelabs Technologies, Inc. (NASDAQ:GNLB), for $1.30 in cash per share without interest and... More...>> |
| 12/03/2008 | 4:30PM | PRNUS | GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc.
LONDON and PHILADELPHIA, Dec. 3 /PRNewswire-FirstCall/ -- GlaxoSmithKline (LSE/NYSE: GSK) announced today that it is waiving a condition relating to a pending lawsuit in the previously announced tender offer to purchase all of the outstanding shares of common stock of Genelabs Technologies, Inc. (NASDAQ:GNLB), for $1.30... More...>> |
| 11/12/2008 | 9:44AM | PRNUS | GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
LONDON, Nov. 12 /PRNewswire-FirstCall/ -- GlaxoSmithKline (LSE/NYSE: GSK) announced today that Gemstone Acquisition Corporation, a wholly-owned subsidiary of GSK, is commencing a cash tender offer to purchase all outstanding shares of common stock of Genelabs Technologies, Inc. (NASDAQ:GNLB), for $1.30 in cash without... More...>> |
| 10/31/2008 | 9:00AM | PRNUS | Beacon Equity Issues Technical Trade Alerts on Market Movers: GNLB, SPSN, PDGI, SIMO, UCTT, CYCL
DALLAS, Oct. 31 /PRNewswire/ -- BeaconEquity.com announces the availability of Trade Alerts on stocks making news today.
Investors can view all of the daily trading notes for free by visiting: http://www.beaconequity.com/m
Today's Trade Alerts include: Genelabs Technologies Inc. (NASDAQ:GNLB), Spansion Inc. (NASDAQ:SPSN... More...>> |
| 10/31/2008 | 9:00AM | PRNUS | Beacon Equity Issues Technical Trade Alerts on Market Movers: GNLB, SPSN, PDGI, SIMO, UCTT, CYCL
DALLAS, Oct. 31 /PRNewswire/ -- BeaconEquity.com announces the availability of Trade Alerts on stocks making news today.
Investors can view all of the daily trading notes for free by visiting: http://www.beaconequity.com/m
Today's Trade Alerts include: Genelabs Technologies Inc. (NASDAQ:GNLB), Spansion Inc. (NASDAQ:SPSN... More...>> |
| 10/29/2008 | 8:44PM | PRNUS | GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C
PHILADELPHIA, Oct. 29 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE:GSK) (LSE:GSK) and Genelabs Technologies, Inc. (NASDAQ:GNLB) announced today that they have entered into a definitive agreement pursuant to which GSK will acquire Genelabs for approximately $57 million (pounds Sterling 35 million) through a tender... More...>> |
| 02/07/2008 | 9:00AM | PRNUS | Genelabs Technologies to Present at the BIO CEO & Investor Conference
REDWOOD CITY, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. (NASDAQ:GNLB) announced today that its Chief Financial Officer Fred Driscoll will present a company update at the BIO CEO Investor Conference at the Waldorf Astoria Hotel Tuesday, February 12, 2008 at 2:00 pm E.T.
The presentation is... More...>> |
| 01/30/2008 | 7:18PM | PRNUS | Genelabs Technologies, Inc. Announces Resignation of President and CEO
Executive Chairman and CFO Assume Leadership Responsibilities; CEO Search Underway
REDWOOD CITY, Calif., Jan. 30 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. (NASDAQ:GNLB) announced today that James A. D. Smith has resigned as President, Chief Executive Officer and Director of the company, effective January... More...>> |
| 11/19/2007 | 7:30AM | PRNUS | Genelabs Technologies Regains Exclusive Rights to Prestara(TM) in Japan From Mitsubishi Tanabe Pharma Corporation
REDWOOD CITY, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. (NASDAQ:GNLB) announced today that it has regained full development and licensing rights in Japan for its investigational lupus drug Prestara(TM) (GL701), under the terms of a termination agreement between the Company and Mitsubishi... More...>> |
| 11/13/2007 | 7:30AM | PRNUS | Genelabs Technologies, Inc. Reports Financial Results for the Third Quarter and First Nine Months of 2007
REDWOOD CITY, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. (NASDAQ:GNLB) today reported revenues of $4.6 million and a net loss of $0.1 million, or $0.00 per share, for the third quarter of 2007. This compares to revenues of $3.6 million and a net loss of $0.6 million, or $0.03 per share, for... More...>> |
| 11/05/2007 | 7:30AM | PRNUS | Genelabs Technologies to Present at the Acumen Biofin Rodman & Renshaw 9th Annual Healthcare Conference
REDWOOD CITY, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. (NASDAQ:GNLB) announced today that the company will be webcasting its corporate presentation at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on Wednesday, November 7th at 8:50 am Eastern Time. The webcast can be... More...>> |
| 10/30/2007 | 7:30AM | PRNUS | Genelabs Technologies Announces Appointment of Frederick W. Driscoll as Chief Financial Officer
REDWOOD CITY, Calif, Oct. 30 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. (NASDAQ:GNLB) today announced the appointment of Frederick W. Driscoll as Chief Financial Officer.
Mr. Driscoll has more than 25 years of financial management and operational experience in the biotechnology and medical device industries... More...>> |
| 10/01/2007 | 5:00PM | PRNUS | Genelabs Technologies Announces Completion of $23.7 Million Registered Direct Financing
Funds to Support Ongoing HCV Drug Discovery Projects
REDWOOD CITY, Calif., Oct. 1 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. (NASDAQ:GNLB) announced today that it has completed its previously announced sale of approximately 12.9 million shares of its common stock and warrants to purchase approximately 2.6... More...>> |
| 09/26/2007 | 8:20AM | PRNUS | Genelabs Technologies Announces Commitments to Raise $23.7 Million in a Registered Direct Financing
Funds to Support Ongoing HCV Drug Discovery Projects
REDWOOD CITY, Calif., Sept. 26 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. (NASDAQ:GNLB) announced today that it has obtained commitments from several institutional investors to purchase approximately 12.9 million shares of its common stock and warrants... More...>> |
| 08/13/2007 | 5:00PM | PRNUS | Genelabs Technologies, Inc. Reports Financial Results for the Second Quarter and First Half of 2007
REDWOOD CITY, Calif., Aug. 13 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. (NASDAQ:GNLB) today reported revenues of $4.7 million and a net loss of $0.4 million, or $0.01 per share, for the second quarter of 2007. This compares to revenues of $2.3 million and a net loss of $4.3 million, or $0.24 per share, for... More...>> |
| 05/14/2007 | 5:00PM | PRNUS | Genelabs Technologies, Inc. Reports First Quarter 2007 Financial Results
REDWOOD CITY, Calif., May 14 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. (NASDAQ:GNLB) today reported revenues of $3.6 million and a net loss of $0.5 million, or $0.02 per share, for the first quarter of 2007. This compares to revenues of $1.7 million and a net loss of $3.4 million, or $0.19 per share, for... More...>> |
| 05/02/2007 | 7:00PM | PRNUS | Genelabs Technologies Announces Presentation of Data on Non-Nucleoside HCV Polymerase Inhibitor at 20th International Conference
REDWOOD CITY, Calif., May 2 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. (NASDAQ:GNLB) announced today that a presentation was made today at the 20th International Conference on Antiviral Research being held in Palm Springs, California, on a non-nucleoside hepatitis C virus (HCV) polymerase inhibitor discovered... More...>> |
|